PRESS RELEASE
Sanford Rose Associates® – Toft Group Places President and CEO of bioTheranostics, Inc.
OCTOBER 6, 2014 – Sanford Rose Associates® – Toft Group an executive search firm that focuses exclusively on assignments for Life Sciences and Healthcare companies, is proud to announce the successful placement of Nicolas Barthelemy as the President and Chief Executive Officer of bioTheranostics, Inc., a San Diego based commercial stage, diagnostic company providing oncologists with a comprehensive suite of tests for metastatic and breast cancer. Barthelemy succeeds Richard Ding, who will remain chairman of the board of bioTheranostics in addition to heading the Asia Pacific operations for parent company bioMérieux.
Mr. Barthelemy joins bioTheranostics with more than twenty years of life sciences and biopharmaceutical experience. Mr. Barthelemy most recently served as Chief Commercial Officer at Life Technologies until the acquisition by Thermo Fisher. Before joining Life Technologies, Mr. Barthelemy held senior executive leadership roles with Biogen Idec, and started his career at Merck, Inc. Mr. Barthelemy received an MS in Chemical Engineering from the University of California, Berkeley, and completed a graduate degree in Chemistry from Ecole Supérieure de Physiques et Chimie Industrielles in Versailles, France.
“I am excited to join the accomplished bioTheranostics team and leverage the support of bioMérieux, as we focus on the next phase of growth. I have a track record of scaling and leading organizations through aggressive growth phases, and I look forward to further establishing bioTheranostics as a world leader in cancer Diagnostics,” said Mr. Barthelemy.
Robin Toft, President and CEO of Sanford Rose Associates® – Toft Group said: “Nicolas has a breadth of international, public company operating, commercial and manufacturing expertise. These qualities, along with his passion to make a difference in healthcare make Nicolas an excellent fit for the bioTheranostics team.”
bioTheranostics, Inc., is a leader in helping physicians improve the care and management of cancer patients, offering a suite of proprietary molecular diagnostic tests that allow treatment to be tailored to individual patients. The company’s Breast Cancer IndexSM helps oncologists make difficult decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients based on its unique ability to predict risk of late disease recurrence and identify which patients are likely to benefit from continuing therapy beyond five years. Its bioT3 Metastatic Cancer Solution combines accurate diagnosis with comprehensive biomarker information that allows improved treatment for metastatic cancer patients. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.
Sanford Rose Associates® – Toft Group (www.sanfordrose.com/toftgroup) is committed to filling Director to Executive-level Management positions exclusively in biotechnology, medical device, diagnostic, pharmaceutical and healthcare companies. Sanford Rose Associates® – Toft Group is Life Sciences focused and the top performing executive search firm within the global Sanford Rose Associates® network, which has over 50 offices worldwide and is a member of the International Executive Search Federation (IESF).
Robin Toft, President and CEO, Sanford Rose Associates – Toft Group at: Phone (925) 837-5800 / Email: [email protected]
